目的:探讨基因重组人红细胞生成素(rhEPO)治疗血液病贫血的临床疗效及其影响因素,为rhEPO治疗血液病贫血的适应证选择提供理论基础.方法:对112例血液病贫血患者给予rhEPO治疗,6 000～10 000 IU,每日或隔日1次,皮下注射,10次为1个疗程,连续应用1～3个疗程,评价临床疗效和不良反应.结果:rhEPO治疗血液病贫血总有效率为61.6%(69/112),其中血液肿瘤缓解组有效率为100.0%(38/38)、血液肿瘤未缓解组有效率为34.6%(18/52)、再生障碍性贫血组有效率为30.0%(3/10)、慢性病贫血组有效率为83.3%(10/12).通过血清内源性促红细胞生成素水平(sEPO)与疗效关系分析,显示sEPO水平低者疗效[96.0%(48/50)]明显优于sEPO水平高者[33.9%(21/62)],未见明显不良反应.结论:rhEPO用于治疗sEPO水平偏低的血液肿瘤缓解后及慢性病贫血患者是有效的,而对于sEPO水平显著增高的贫血和其他血液肿瘤未缓解者疗效不理想.%Objective: To investigate the effect of recombinant human erythropoietin (rhEPO) in the treatment of hematologic patients with anemia. Methods: 112 patients in hematologic with anemia were treated by rhEPO, 6 000-10 000 IU, ih, qd or qod, for 10 days consisted of one course and every patient was received 1-3 courses of treatment. The clinical efficacy and adverse reactions of them were evaluated. Results: In all 112 patients in hematologic with anemia, the total efficiency rate was 61.6%(69/112), efficiency rate in anemia with patients with remission tumor was 100.0%(38/38), patients with no-remission tumor was 34.6% (18/52), AA was 30.0% (3/10), ACD was 83.3% (10/12). The efficiency rate in patients of sEPO lower level was [96.0%(48/50)], and it was better than that of patients of sEPO higher level [33.9%(21/62)]. There was no adverse reactions happened. Conclusion: The rhEPO is efficacious for anemia with patients in remission tumor and anermia of chronic disease, but with lowly efficacious in treating no-remission tumor .
展开▼
